Skip to main content
. 2021 Mar 22;45(6):665–675. doi: 10.1016/j.jgr.2021.03.003

Fig. 4.

Fig. 4

Rg1 treatment reduced Aβ deposition in APP/PS1 mice. (A) The bands of APP, CTF-β, BACE, NCSTN and β-actin (Western blot); (B-E) The relative expression of APP, CTF-β, BACE and NCSTN over WT-9M; (F–H) The relative mRNA expressions of APP, BACE and NCSTN (q-PCR); (I) The Aβ deposition in cortex and hippocamus (Thioflavin-S staining, 20 × , the bar = 500 μm, yellow arrows indicate Aβ deposition); (J) The ratio of Aβ plaque load (%) in cortex and hippocampus; (K) The bands of Aβ1-42 and β-actin (Western blot); (L) The relative expression of Aβ1-42 over WT-9M. (M) The bands of TAU and p-TAU (Western blot); (N) The relative expression of p-TAU/TAU over WT-9M. Results are expressed as mean ± SD, Thioflavin-S staining, n = 5; other experiments, n = 4. ∗P < 0.05, ∗∗P < 0.01 vs WT-9M group; #P < 0.05, ##P < 0.01 vs APP/PS1-6M group; ΔP<0.05, ΔΔP<0.01 vs APP/PS1-9M group.